TorreyPines shelves drug discovery and cuts staff
This article was originally published in Scrip
Executive Summary
TorreyPines Therapeutics is to abandon its drug discovery operations as part of a strategic plan that will halve its workforce. The US firm will cut staff to lower its spending and become a development-only business.